Amneal Pharmaceuticals agreed to acquire Kashiv BioSciences for $1.1 billion, consisting of $375 million in cash, $375 million in equity, and up to $350 million in milestones. 1 2 The deal provides Amneal control of four manufacturing facilities: one in Chicago, one in New Jersey (6,000 L capacity expanding to 24,000 L), and two in India (one expanding to 50,000 L). 1 Amneal's co-CEOs, Chirag and Chintu Patel, own half of Kashiv directly or indirectly. 1 The acquisition supports Amneal's biosimilar pipeline, including six launches by next year with $14B market potential (led by Xolair biosimilar at $4.6B) and another six from 2028-2030 with $42B potential, including Keytruda and Trulicity copies. 1 Capacity will scale from 26,000 liters in 2026 to 75,000 by 2028, with $30-50M annual capex; infrastructure allows further 25,000L additions. 1 Prior collaborations include licensing Neulasta/Neupogen biosimilars (approved 2022 as Fylnetra/Releuko) in 2017 and Xolair in 2...
- Get link
- X
- Other Apps